211 related articles for article (PubMed ID: 32319653)
1. Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model.
Tan QL; Zhou CY; Cheng L; Luo M; Liu CP; Xu WX; Zhang X; Zeng X
Mol Med Rep; 2020 Jul; 22(1):362-370. PubMed ID: 32319653
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
Luo Y; Han R; Evanoff DP; Chen X
Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
[TBL] [Abstract][Full Text] [Related]
4. 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer.
Hsu JW; Yin PN; Wood R; Messing J; Messing E; Lee YF
Oncotarget; 2013 Dec; 4(12):2397-406. PubMed ID: 24353168
[TBL] [Abstract][Full Text] [Related]
5. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
6. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
Simons MP; Nauseef WM; Griffith TS
Immunol Res; 2007; 39(1-3):79-93. PubMed ID: 17917057
[TBL] [Abstract][Full Text] [Related]
7. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
8. [Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer].
Krajewski W; Kołodziej A; Dembowski J; Zdrojowy R
Postepy Hig Med Dosw (Online); 2014 Mar; 68():291-300. PubMed ID: 24662797
[TBL] [Abstract][Full Text] [Related]
9. The role of cancer stem cells in immunotherapy for bladder cancer: An in vitro study.
Özcan Y; Çağlar F; Celik S; Demir AB; Erçetin AP; Altun Z; Aktas S
Urol Oncol; 2020 May; 38(5):476-487. PubMed ID: 32192892
[TBL] [Abstract][Full Text] [Related]
10. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.
Luo Y; Knudson MJ
Clin Dev Immunol; 2010; 2010():357591. PubMed ID: 20862387
[TBL] [Abstract][Full Text] [Related]
12. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
13. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
14. Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.
Luo Y; Yamada H; Evanoff DP; Chen X
Clin Exp Immunol; 2006 Oct; 146(1):181-8. PubMed ID: 16968412
[TBL] [Abstract][Full Text] [Related]
15. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.
Bevers RF; Kurth KH; Schamhart DH
Br J Cancer; 2004 Aug; 91(4):607-12. PubMed ID: 15266312
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guérin immunotherapy induces an efficient antitumor response to control murine melanoma depending on MyD88 signaling.
Borges VM; Marinho FV; Caldeira CVA; de Queiroz NMGP; Oliveira SC
Front Immunol; 2024; 15():1380069. PubMed ID: 38835781
[TBL] [Abstract][Full Text] [Related]
17. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
[TBL] [Abstract][Full Text] [Related]
18. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
19. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
20. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
